PRNewsWire
01 Sept 2026, 10:30 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Medtronic will become the exclusive global commercial distributor of Pi-Cardia's FDA-cleared ShortCut device in 2027. — Exclusive distribution of a first-of-its-kind FDA-cleared device expands Medtronic's market reach and recurring revenue potential in the structural heart segment.
+0.40Medtronic has an option to acquire Pi-Cardia for an estimated upfront price of up to $210 million plus additional earn-out payments upon meeting predefined milestones. — Provides a clear path to full integration of the technology with a capped upfront cost, reducing the risk of overpaying for an unproven asset.
+0.30Medtronic is making strategic investments of up to $80 million into Pi-Cardia. — The investment is a relatively small capital expenditure for a company of Medtronic's size, though it signals strategic commitment to the TAVR space.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is strategically expanding its structural heart portfolio through an investment and distribution agreement for an FDA-cleared technology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
